Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in Organ Transplant Recipients with Advanced cSCC
NCT04339062Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2020
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Dana-Farber Cancer Institute. Started Nov 2020; status: completed.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04339062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339062.